PRE-FUNDED COMMON STOCK PURCHASE WARRANT ONCONOVA THERAPEUTICS, INC.Pre-Funded Common Stock Purchase Warrant • April 25th, 2018 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 25th, 2018 Company Industry JurisdictionTHIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “ Holder “) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), but not thereafter, to subscribe for and purchase from Onconova Therapeutics, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
] Shares of Common Stock Pre-Funded Warrants to Purchase [ ] Shares of Common Stock and [ ] Warrants to Purchase [ ] Shares of Series B Convertible Preferred Stock Onconova Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • April 25th, 2018 • Onconova Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledApril 25th, 2018 Company Industry
SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT ONCONOVA THERAPEUTICS, INC.Warrant Agreement • April 25th, 2018 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 25th, 2018 Company Industry JurisdictionTHIS PREFERRED STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the 18-month anniversary of the date (the “Charter Amendment Date”) on which the Company (as defined below) publicly announces through the filing of a Current Report on Form 8-K that the amendment to the Company’s certificate of incorporation to sufficiently increase the Company’s authorized shares of Common Stock to cover the conversion of all then-outstanding shares of Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware (the “Termination Date”), provided that, if such date is not a Trading Day, the Termination Date should be the immediately following Trading Day but not thereafter, to